YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
RNA therapeutics are medicines that use RNA molecules to influence gene expression or protein production. Unlike many conventional drugs that act directly on proteins, RNA medicines can intervene earlier in the process by reducing disease-…
[Stethoscope and white card with RARE DISEASES text on blue background.] Zolak/iStock via Getty Images Arcturus Therapeutics (ARCT [https://seekingalpha.com/symbol/ARCT]) said that interim phase 2 results for ARCT-810 showed the candidate…
SAN DIEGO, September 18, 2026--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics,…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio Messenger RNA drug developers Arcturus Therapeutics (ARCT [https://seekingalpha.com/symbol/ARCT]) and Moderna (MRNA [https://see…
The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers Continue Reading
The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers Continue Reading
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Editor's Note: The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA…
Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run. Continue Reading
Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run. Continue Reading
Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:M…
Key Points Interested in Arcturus Therapeutics Holdings Inc.? Here are five stocks we like better. ARCT-032 cystic fibrosis study remains on track: Phase II enrollment is active in the U.S., Israel and Turkey, focusing on patients with Cla…
Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This…
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago. These figures are adjusted for non-recur…
Arcturus Therapeutics (ARCT) shares rallied 5.7% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the sto…
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights SAN DIEGO, July 02, 2026--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. ("Arcturus", Nasdaq: ARCT), a messenger RNA medicines com…
Illumina (ILMN) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items. This…
Joe Raedle Cathie Wood’s ARK Invest funds executed a broad rotation across technology, healthcare, and industrial names during the last week while markets remained volatile over broader geopolitical tensions between the U.S. and Iran. Buyi…
Cathie Wood’s ARK Invest has been steadily dialing down its exposure to mega-cap tech, trimming names like Nvidia (NVDA), Meta (META), AMD (AMD), and Tesla (TSLA) amid valuation and regulatory concerns. But at the same time, the firm is ro…
It seems as if Cathie Wood can't have nice things. The founder and CEO of the Ark Invest family of aggressive-growth exchange-traded funds (ETFs) had a market-thumping performance in 2020, only to fall short for a few years. She came throu…
Key Points Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling con…
Last week was challenging for most investors. The three major market indexes moved lower for the fourth consecutive week. Growing investing icon Cathie Wood -- the founder, CEO, and primary stock picker of Ark Invest's family of ETFs -- ha…
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 MANAGEMENT VIEW * CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing with higher dose tes…
* Arcturus Therapeutics press release [https://seekingalpha.com/pr/20422782-arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2025-financial-results-and] (ARCT [https://seekingalpha.com/symbol/ARCT]): FY GAAP EPS of -$2.40 mis…
* Arcturus Therapeutics (ARCT [https://seekingalpha.com/symbol/ARCT]) is scheduled to announce Q4 earnings results on Tuesday, March 3rd, after market close. * The consensus EPS Estimate is -$0.76 [https://seekingalpha.com/symbol/ARCT/earn…
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly…
We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while maintaining a Neutral rating, reflecting a…
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The seventeenth stock on our list is Arcturus Therapeutics Holdings Inc. TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy…
Arcturus Therapeutics Holdings (ARCT) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. This event is a forum where management often outlines pipeline progress and capital priorities. See our lates…
Stocks trading under $10 rarely come with the potential for life-changing gains, especially in today’s cautious market. In most sectors, that kind of upside is almost unheard of. Some biotech stocks, however, are an exception. When encoura…
Health care stocks were leaning lower premarket Wednesday, with the State Street Health Care Select PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and satel…
This article first appeared on GuruFocus. Cathie Wood's ARK Invest funds shifted positions Monday, increasing stakes in Chinese tech giant Baidu (BIDU) while trimming exposure to Tesla (NASDAQ:TSLA). The ARK Innovation ETF (ARKK) purchased…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction…
Shares of Arcturus Therapeutics ARCT have plunged 59.4% in the past three months. The massive stock price drop was primarily due to the mixed nature of the interim results reported by ARCT in late October from an ongoing mid-stage study ev…
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 MANAGEMENT VIEW * CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "trea…
Fate Therapeutics (FATE) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's e…